Clinical trial
Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial…
NCT00456248 · Kadmon Corporation, LLC, Industry · Terminated
Key facts
| NCT number | NCT00456248 |
|---|---|
| Title | Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin |
| Official title | Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy |
| Acronym | ENHANCE |
| Lead sponsor | Kadmon Corporation, LLC, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Hepatitis C |
| Intervention type | Drug |
| Interventions | Infergen and ribavirin |
| Enrollment | 5 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Apr 4, 2007 |
| Last update posted | Oct 15, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: